You are here

Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study.

TitleTestosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study.
Publication TypeJournal Article
Year of Publication2014
AuthorsShores, MM, Biggs, ML, Arnold, AM, Smith, NL, Longstreth, WT, Kizer, JR, Hirsch, CH, Cappola, AR, Matsumoto, AM
JournalJ Clin Endocrinol Metab
Volume99
Issue6
Pagination2061-8
Date Published2014 Jun
ISSN1945-7197
KeywordsAged, Aged, 80 and over, Cardiovascular Diseases, Cause of Death, Dihydrotestosterone, Humans, Incidence, Longitudinal Studies, Male, Mortality, Residence Characteristics, Risk Factors, Testosterone
Abstract<p><b>CONTEXT: </b>Low testosterone (T) is associated with prevalent cardiovascular disease (CVD) and mortality. DHT, a more potent androgen, may also be associated with CVD and mortality, but few studies have examined this.</p><p><b>OBJECTIVE: </b>The study objective was to examine whether T and DHT are risk factors for incident CVD and mortality.</p><p><b>DESIGN: </b>In a longitudinal cohort study, we evaluated whether total T, calculated free T (cFT), DHT, and calculated free DHT were associated with incident CVD and mortality in men in the Cardiovascular Health Study (mean age 76, range 66-97 years) who were free of CVD at the time of blood collection.</p><p><b>MAIN OUTCOME: </b>The main outcomes were incident CVD and all-cause mortality.</p><p><b>RESULTS: </b>Among 1032 men followed for a median of 9 years, 436 incident CVD events and 777 deaths occurred. In models adjusted for cardiovascular risk factors, total T and cFT were not associated with incident CVD or all-cause mortality, whereas DHT and calculated free DHT had curvilinear associations with incident CVD (P < .002 and P = .04, respectively) and all-cause mortality (P < .001 for both).</p><p><b>CONCLUSIONS: </b>In a cohort of elderly men, DHT and calculated free DHT were associated with incident CVD and all-cause mortality. Further studies are needed to confirm these results and to clarify the underlying physiologic mechanisms.</p>
DOI10.1210/jc.2013-3576
Alternate JournalJ. Clin. Endocrinol. Metab.
PubMed ID24628549
PubMed Central IDPMC4037728
Grant List1R01HL091952 / HL / NHLBI NIH HHS / United States
U01 HL080295 / HL / NHLBI NIH HHS / United States
N01HC55222 / HL / NHLBI NIH HHS / United States
N01HC85086 / HL / NHLBI NIH HHS / United States
HHSN268201200036C / HL / NHLBI NIH HHS / United States
R01 HL080295 / HL / NHLBI NIH HHS / United States
N01HC85082 / HL / NHLBI NIH HHS / United States
N01HC85083 / HL / NHLBI NIH HHS / United States
HL080295 / HL / NHLBI NIH HHS / United States
R01 HL091952 / HL / NHLBI NIH HHS / United States
AG-023629 / AG / NIA NIH HHS / United States
N01HC85079 / HL / NHLBI NIH HHS / United States
R01 AG023629 / AG / NIA NIH HHS / United States
N01HC85080 / HL / NHLBI NIH HHS / United States
R56 AG023629 / AG / NIA NIH HHS / United States
N01HC85081 / HL / NHLBI NIH HHS / United States